Sonnet BioTherapeutics Holdings Inc (SONN) Actualités

Sonnet Releases Virtual Investor "What This Means" Segment

- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss...

Form 8-K - Current report

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab...

Form 8-K - Current report

Sonnet Announces Release of Corporate Update Video

PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the...

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the...

Form 8-K - Current report

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved...

Form 8-K - Current report

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Company advancing development of its modified version of Interleukin-18 (IL-18Binding Protein Resistant or...

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here  PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Sonnet...

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Building on proven targeting of the FHAB domain, Sonnet’s ADC platform offers flexible payload capacity and...